The world leader in artificial intelligence (AI) drug discovery, Syntekabio (226330.KQ), today announced that it will be attending the next Bio-IT World Conference & Expo.
The business recently introduced STB LaunchPad, a patented disease-agnostic technology platform developed by Syntekabio that can produce hits, leads, and drug candidates against a variety of targets, along with its drug discovery services in the US and Europe. In collaboration with its international network of contract research organizations (CROs), viable leads undergo additional optimization and experimental validation before an IND-enabling package is provided to the customer.
CEO of Syntekabio USA Inc. Jonathan Witztum, PhD, stated: “It’s exciting to formally launch our US activities during BIO-IT World.” We can quickly move clients from target to IND with our cutting-edge technology and significant processing power, providing first- or best-in-class compounds for a range of indications in less than two years. We are thrilled to be able to provide these services to clients in the US and Europe, and we eagerly await the opportunity to meet with prospective customers to go over in more depth the benefits our services can give to their drug discovery and development initiatives.
Bio-IT World Congress & Exhibition
15–17 April, Boston, MA, USA
Being a Gold Sponsor of this industry event that showcases the newest technological advancements for the life sciences sector, Syntekabio is proud to be a part of this important industry gathering.
Don’t Let Patients Wait: Combining Wet-Lab and AI to Deliver Viable Drug Candidates Quickly
Emilia Kruzel, PhD, Vice President of Business Development at Syntekabio, is the presenter.
April 17, Wednesday, 12:40 p.m. EST
Artificial intelligence (AI) technologies can accelerate drug discovery and improve data processing, but they still need a lot of experimental validation and case-by-case customization. Dr. Kruzel will discuss Syntekabio’s disease-neutral method of AI-driven drug development that produces effective treatment candidates. Combining cloud, AI, and biological technologies, Syntekabio operates like a factory, producing new and promising treatment candidates for a variety of illnesses on a constant basis. Avoid making the patients wait is the aim.
